Holen Sie sich die Stockscreener-App
99.21
0.31%
-0.31
Vorhandelsmarkt:
102.00
2.79
+2.81%
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics: Q1 Earnings Snapshot - wwltv.com
Protagonist Therapeutics, Inc. Q1 2026 Financial Report – SEC Filing, Balance Sheets, and Management Discussion - Minichart
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS - MarketBeat
Milestones and Takeda opt-out reshape Protagonist (NASDAQ: PTGX) outlook - Stock Titan
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist (NASDAQ: PTGX) posts Q1 profit amid ICOTYDE approval and $200M rusfertide opt-out - Stock Titan
Protagonist Therapeutics set to report as blockbuster bets grow - Investing.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MSN Money - MSN
Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock - Insider Monkey
331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC - MarketBeat
M&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
Vanguard shows 5.09% stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Pictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Vanguard reports 3.53M-share stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating - Moomoo
Blood cancer drug translates into $200 million payday for Bay Area company — and there's more to come - The Business Journals
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Moody Aldrich Partners LLC - MarketBeat
UBS Group AG Acquires 874,013 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
[ARS] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
Protagonist Therapeutics (NASDAQ: PTGX) plans 2026 meeting and expanded equity plan - Stock Titan
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
Takeda (TAK) and Protagonist Therapeutics Deal Revisited - GuruFocus
Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical - marketscreener.com
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration - Voice of Alexandria
Takeda takes U.S. rights to rusfertide; Protagonist eligible for $475M - Stock Titan
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics Shifts Focus to High Margin Commercial Royalties - HarianBasis.co
Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock - Yahoo Finance
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
CEO of Protagonist (NASDAQ: PTGX) makes bona fide share gift - Stock Titan
PTGX News | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
PTGX (Protagonist Therapeutics Inc.) rises 2.17 percent even as Q4 2025 EPS falls far below analyst consensus estimates.Profit Guidance - UBND thành phố Hải Phòng
How (PTGX) Movements Inform Risk Allocation Models - Stock Traders Daily
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight - GlobeNewswire Inc.
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 1,750 Shares of Stock - MarketBeat
Protagonist Therapeutics CFO Ali Asif sells $184,572 in shares - Investing.com
Protagonist Therapeutics CFO Ali Asif sells $184,572 in shares By Investing.com - Investing.com Australia
Protagonist Therapeutics (NASDAQ: PTGX) CFO sells shares to cover RSU taxes - Stock Titan
PTGX (NASDAQ) Form 144: 1,750-share sale noted; insider disposals listed - Stock Titan
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Protagonist Therapeutics (PTGX) price target increased by 11.65% to 114.50 - MSN
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Two new hires get rights to 69,850 Protagonist shares in awards - Stock Titan
PTGX Maintained by Truist Securities -- Price Target Raised to $121 - GuruFocus
Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com
Polycythemia Vera Market: Rapid Increment Driven by Innovation - openPR.com
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $121 - Moomoo
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $112 - Moomoo
Protagonist Therapeutics (PTGX) Stock Price Target Hike (Investor Interest) 2026-04-15Momentum Signals - UBND thành phố Hải Phòng
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):